BioSpace News Archive

The demand within the global animal healthcare market is set to touch new heights in the years to follow.

Aptitude’s Axess Network provides Excelera members with cutting-edge clinical and market insights in oncology and hematology as well as unparalleled access to disease-state experts and their clinical practices

IVERIC bio, Inc., announced the pricing of an upsized underwritten public offering of 24,535,720 shares of its common stock at a price to the public of $4.100 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 1,914,280 shares of its common stock at a price to the public of $4.099 per pre-funded warrant, in each case less underwriting discounts and commissions.

The competitive scenario of the global Picture Archiving and Communication System and Radiology Information System market is anticipated to appear highly consolidated.

A new research study that has been presented by Transparency Market Research states that the global market for medical specialty bags is likely to observe a promising strong competition among the players over the next few years.

The global assistive technologies for visually impaired market is projected to achieve a considerable valuation in the next few years of the given forecast period.

Codagenix, Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, today announced the successful synthesis of a readily-scalable live-attenuated vaccine candidate against COVID-19. The vaccine, CDX-005, is currently undergoing safety and efficacy studies in animals and appears m

Renovion, Inc., a biopharmaceutical company on a mission to transform the treatment of chronic inflammatory lung diseases, announced completion of a Series A financing round of $8.1 million to fund the development and clinical programs associated with their lead therapeutic candidate ARINA-1. ARINA-1 is a nebulized therapy developed to improve mucus clearance and

June 18, 2020 12:00 UTC - Advancing medicines to transform the lives of patients with life-limiting diseases of the nervous system SAN DIEGO--( BUSINESS WIRE )-- Engrail Therapeutics™ (Engrail) (the Company) today announced the close of a $32 million Series A financing round. Nan Fung Life Sciences (NFLS), the global investment platform of the Nan Fung Group, led the round. The Company plans to use the proceeds from the financing to support the clinical development of its f

Pear Therapeutics Announces Market Authorization of reSET ® from the Health Science Authority in Singapore for the Treatment of Adults with Substance Use Disorder HSA’s positive decision marks Pear’s first regulatory authorization outside of U.S. reSET is the first HSA-authorized prescription digital therapeutic to be available in Singapore BOSTON & SAN FRANCISCO--( BUSINESS WIRE )-- Pear Therapeutics, Inc. today announced that the